Also, CRISPR/Cas9 was utilized to modify the BCL11A enhancer sequence in hematopoietic stem cells (HSCs), leading to reduced BCL11A enhancer expression and increased production of fetal hemoglobin and gamma-globin, benefiting sickle cell disease and transfusion-dependent beta-thalassemia patients [27]. Here, BCL11A is linked to Beta-thalassemia.